These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9730561)

  • 1. Low molecular weight heparin reduces triglyceride, VLDL and cholesterol/HDL levels in hyperlipidemic diabetic patients on hemodialysis.
    Yang C; Wu T; Huang C
    Am J Nephrol; 1998; 18(5):384-90. PubMed ID: 9730561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparin in diabetic and nondiabetic hypercholesterolemic patients receiving long-term hemodialysis.
    Leu JG; Liou HH; Wu SC; Yang WC; Huang TP; Wu SC
    J Formos Med Assoc; 1998 Jan; 97(1):49-54. PubMed ID: 9481065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis.
    Lai KN; Ho K; Cheung RC; Lit LC; Lee SK; Fung KS; Tong MK; Lam CW
    Int J Artif Organs; 2001 Jul; 24(7):447-55. PubMed ID: 11510916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of conventional vs. low-molecular-weight heparin on lipid profile in hemodialysis patients.
    Elisaf MS; Germanos NP; Bairaktari HT; Pappas MB; Koulouridis EI; Siamopoulos KC
    Am J Nephrol; 1997; 17(2):153-7. PubMed ID: 9096446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.
    Shoji T; Nishizawa Y; Kawagishi T; Tanaka M; Kawasaki K; Tabata T; Inoue T; Morii H
    Atherosclerosis; 1997 Jun; 131(2):229-36. PubMed ID: 9199276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of low molecular weight heparin on lipid parameters in hemodialysis patients.
    Elisaf MS; Bairaktari H; Germanos N; Pappas M; Koulouridis E; Papagalanis N; Siamopoulos KC
    Int Angiol; 1996 Sep; 15(3):252-6. PubMed ID: 8971586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of serum lipids and lipoproteins in Ethiopian diabetic patients.
    Seyoum B; Abdulkadir J; Berhanu P; Feleke Y; Mengistu Z; Worku Y; Ayana G
    Ethiop Med J; 2003 Jan; 41(1):1-8. PubMed ID: 12764995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of various heparin preparations on lipoproteins in hemodialysis patients: a multicentre study.
    Kronenberg F; König P; Neyer U; Auinger M; Pribasnig A; Meisl T; Pinter G; Dieplinger H
    Thromb Haemost; 1995 Oct; 74(4):1025-8. PubMed ID: 8560405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-molecular-weight heparin (LMWH): influence on blood lipids in patients on chronic haemodialysis.
    Schmitt Y; Schneider H
    Nephrol Dial Transplant; 1993; 8(5):438-42. PubMed ID: 8393549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients.
    Janssen MJ; Deegens JK; Kapinga TH; Beukhof JR; Huijgens PC; van Loenen AC; van der Meulen J
    Kidney Int; 1996 Mar; 49(3):806-13. PubMed ID: 8648924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
    Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F
    Nephron; 2002; 92(3):589-600. PubMed ID: 12372942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients.
    Desmeules S; Arcand-Bossé JF; Bergeron J; Douville P; Agharazii M
    Am J Kidney Dis; 2005 Jun; 45(6):1067-72. PubMed ID: 15957136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Low molecular weight heparin: how does it modify lipid metabolism in chronic hemodialysis patients?].
    Schneider H; Schmitt Y
    Klin Wochenschr; 1991 Oct; 69(16):749-56. PubMed ID: 1662323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of olbetam on hyperlipidemia in NIDDM].
    Yu Y; Liang J; Zhang X
    Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):427-9. PubMed ID: 8732067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hyperlipemia in diabetic patients on dialysis with a physiological substance.
    Coronel F; Tornero F; Torrente J; Naranjo P; De Oleo P; Macia M; Barrientos A
    Am J Nephrol; 1991; 11(1):32-6. PubMed ID: 2048576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of diabetic control on very low-density lipoprotein--triglyceride metabolism in patients with type II diabetes mellitus and marked hypertriglyceridemia.
    Dunn FL; Raskin P; Bilheimer DW; Grundy SM
    Metabolism; 1984 Feb; 33(2):117-23. PubMed ID: 6582347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients.
    Chen ST; Ferng SH; Yang CS; Peng SJ; Lee HR; Chen JR
    Am J Kidney Dis; 2005 Dec; 46(6):1099-106. PubMed ID: 16310576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients.
    Kronenberg F; König P; Lhotta K; Steinmetz A; Dieplinger H
    Clin Nephrol; 1995 Jun; 43(6):399-404. PubMed ID: 7554525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [When lipids increase in dialysis: the role of heparin! Standard heparin increases, low-molecular-weight heparin lowers triglycerides].
    Wiemer J; Scherberich JE
    MMW Fortschr Med; 1999 Oct; 141(43):29-32. PubMed ID: 10912118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol-lowering effect of concentrated pomegranate juice consumption in type II diabetic patients with hyperlipidemia.
    Esmaillzadeh A; Tahbaz F; Gaieni I; Alavi-Majd H; Azadbakht L
    Int J Vitam Nutr Res; 2006 May; 76(3):147-51. PubMed ID: 17048194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.